| |
Original Artikel |
Datum |
Titel |
Autoren Alle Autoren |
| 1 |
[GO] |
2025―Feb―03 |
Potent SARS-CoV-2 3C-like protease inhibitor ( +)-eupenoxide-3,6-diketone (IC50: 0.048 μM) was synthesized based on ( +)-eupenoxide; lead from ( +)-eupenoxide analogs study by endophytic fermentation |
Shoji Maehara, Moeka Kumamoto, Shogo Nakajima, Yuhzo Hieda, Koichi Watashi, Toshiyuki Hata |
| 2 |
[GO] |
2024―Nov―25 |
Sulfoquinovosyl diacylglycerol, a component of Holy Basil Ocimum tenuiflorum, inhibits the activity of the SARS-CoV-2 main protease and viral replication in vitro |
Hinako Koze, Masayuki Sudoh, Satoaki Onitsuka, Hiroaki Okamura, Takeshi Ishikawa, Fumito Tani, et al. (+5) Yukako Miyata-Yabuki, Mikako Shirouzu, Masanori Baba, Mika Okamoto, Toshiyuki Hamada |
| 3 |
[GO] |
2024―Mai―22 |
Anti-coronavirus and anti-pulmonary inflammation effects of iridoids, the common component from Chinese herbal medicines for the treatment of COVID-19 |
Dan-Yu Huang, Yong-Xin Luo, Wen-De Zheng, Shu-Yu Wu, Pei-Qi Huang, Jing-Wei Jin, et al. (+2) Pan-Pan Wu, Li-She Gan |
| 4 |
[GO] |
2024―Mrz―21 |
Inhibitory effects of senkyuchachosan on SARS-CoV-2 papain-like protease activity in vitro |
Yuka Kiba, Takashi Tanikawa, Tsuyoshi Hayashi, Takami Yokogawa, Aiko Sano, Ryuichiro Suzuki, Masashi Kitamura |
| 5 |
[GO] |
2022―Jan―10 |
The discovery of herbal drugs and natural compounds as inhibitors of SARS-CoV-2 infection in vitro |
Mya Myat Ngwe Tun, Kazufumi Toume, Elizabeth Luvai, Khine Mya Nwe, Shusaku Mizukami, Kenji Hirayama, et al. (+2) Katsuko Komatsu, Kouichi Morita |
| 6 |
[GO] |
2021―Okt―23 |
Correction to: Leveraging knowledge of Asian herbal medicine and its active compounds as COVID-19 treatment and prevention |
Desy Liana, Anuchit Phanumartwiwath |
| 7 |
[GO] |
2021―Okt―09 |
Leveraging knowledge of Asian herbal medicine and its active compounds as COVID-19 treatment and prevention |
Desy Liana, Anuchit Phanumartwiwath |
|
